Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cancers|August 12, 2022
Conventional Therapeutics in BPDCN Patients-Do They Still Have a Place in the Era of Targeted Therapies?Margaux Poussard, Fanny Angelot-Delettre, Eric Deconinck
Iscience|June 22, 2026
Metformin dual-targets metabolism and survival pathways in BPDCNZineb Mekkaoui, Ludivine Dal Zuffo, Mathieu Vetter, et al.
Cancers|July 9, 2022
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T CellsBlandine Caël, Jeanne Galaine, Isabelle Bardey, et al.
Ejhaem|August 22, 2025
Venetoclax in the Therapeutic Strategy for BPDCN ManagementMargaux Poussard, Maxime Fredon, Imane Belakri, et al.
Ejhaem|July 18, 2022
BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicityMargaux Poussard, Laure Philippe, Maxime Fredon, et al.
Haematologica|February 5, 2026
Pivekimab sunirine in blastic plasmacytoid dendritic cell neoplasm: assessing spatial response and unraveling resistance mechanismsMargaux Poussard, Morgane Boichut, Imane Belakri, et al.
Cancer Immunology Research|May 31, 2024
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T CellsMaxime Fredon, Margaux Poussard, Sabeha Biichlé, et al.
Leukemia|March 1, 2020
CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasmElodie Bôle-Richard, Maxime Fredon, Sabeha Biichlé, et al.
Pageof 1